Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL
NCT06879262
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
R/R NHL
Interventions
BIOLOGICAL:
CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）
Sponsor
Tongji Hospital